オプションチェーンは、Evotecの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Evotecの市場センチメントを評価します。.

Evotec (NASDAQ:EVO) 株価情報, オプションチェーン

Evotec

Eaton Vance Ohio Municipal Income Trust Shares of Beneficial Interest

Eaton Vance Ohio Municip

Eaton Vance Ohio

Eaton Vance Ohio Municipal Income Trust

AMEX

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec SE

EVO TRANSPORTATION by EVO Transportation & Energy Services, Inc.

EVO Transportation & Energy Services Inc

EVOAIR HOLDINGS INC by EvoAir Holdings Inc.

EvoAir Holdings Inc

EvoAir Holdings Inc Ordinary Shares

Evoke Pharma Inc

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

Envoy Technologies Inc

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Wednesday.
Shares of DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) fell sharply in pre-market trading following <a href="https://www.benzinga.com/quote/DHT/earnings">downbeat quarterly sales</a>.
DHT Holdings reported quarterly earnings of 27 cents per share which beat the analyst consensus estimate of 23 cents per share. The company reported quarterly sales of $79.34 million which missed the analyst consensus estimate of $89.37 million.
DHT Holdings shares fell 3.2% to $11.39 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Compass Diversified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>) shares dipped 13.5% to $6.50 in pre-market trading after the company announced it entered into a diversified forbearance agreement and cut its management fees and quarterly dividend. Additionally, the company received a NYSE late filing notice amid an investigation into financial irregularities for its subsidiary.</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) fell 12.8% to $109.35 in pre-market trading following the company&#8217;s first-quarter earnings report. In its outlook, the company said it is now factoring in potential risks related to the uncertain economic environment for the remainder of FY26.</li>
<li>Galaxy Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) shares tumbled 8.5% to $19.90 in pre-market trading after the company announced a public offering of 29 million shares of common stock.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares declined 6.3% to $25.42 in pre-market trading after announcing the pricing of public offering of ADSs.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) fell 5.8% to $31.02 in pre-market trading.</li>
<li>Cytek Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) declined 4.7% to $2.45 in pre-market trading.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 4.3% to $4.0900 in pre-market trading following a 10% decline on Tuesday.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) fell 4.3% to $45.79 in pre-market trading.</li>
<li>IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) declined 3.7% to $46.25 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CODI

CTKB

DXYZ

GLXY

IONQ

OKTA

DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock rose 152.4% to $1.05 during Friday's regular session. The company's market cap stands at $15.3 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 27.6% to $1.09. The market value of their outstanding shares is at $144.8 million. </li>
<li>ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) shares rose 19.42% to $8.57. The market value of their outstanding shares is at $149.6 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares rose 17.66% to $1.56. The company's market cap stands at $159.0 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock moved upwards by 17.61% to $4.74. The company's market cap stands at $1.6 billion. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares increased by 15.18% to $4.93. The market value of their outstanding shares is at $38.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares fell 43.0% to $8.93 during Friday's regular session. The company's market cap stands at $487.0 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 20.81% to $3.25. The market value of their outstanding shares is at $2.5 million. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock declined by 20.43% to $8.92. The market value of their outstanding shares is at $785.8 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) stock decreased by 20.13% to $1.93. The market value of their outstanding shares is at $53.6 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock declined by 19.43% to $2.78. The market value of their outstanding shares is at $2.7 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares fell 16.61% to $0.07. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTS

BCAX

GYRE

IMMX

IMNN

LUCD

ONCO

RADX

RAPT

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares rose 17.3% to $0.95 during Friday's pre-market session. The market value of their outstanding shares is at $38.3 million. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock moved upwards by 11.21% to $11.6. The market value of their outstanding shares is at $219.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares increased by 10.18% to $1.73. The market value of their outstanding shares is at $79.0 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock moved upwards by 10.0% to $1.32. The company's market cap stands at $86.9 million. </li>
<li>Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) shares moved upwards by 9.47% to $6.7. The market value of their outstanding shares is at $361.6 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock rose 9.42% to $4.41. The market value of their outstanding shares is at $1.5 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares declined by 20.7% to $12.42 during Friday's pre-market session. The market value of their outstanding shares is at $677.3 million. </li>
<li>Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) shares fell 16.5% to $2.01. The market value of their outstanding shares is at $56.1 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) shares fell 14.64% to $1.4. The market value of their outstanding shares is at $46.9 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 13.67% to $1.2. The company's market cap stands at $3.0 million. </li>
<li>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares decreased by 8.31% to $0.31. The company's market cap stands at $7.1 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 7.84% to $0.51. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BDRX

BRNS

BWAY

FULC

IOBT

OTLK

PDSB

TSBX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<ul>
<li>Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.</li>
<li>The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.</li>
</ul>

Evotec Secures $2.5M Grant To Generate Critical Data Supporting New TB Regimens

Earnings

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

GUIDANCE FOR FULL-YEAR 2025 } Group revenues expected in the range of € 840 m to € 880 m (FY 2024: € 797.0 m) } R&amp;D expenditures are expected in a range of € 40 m to € 50 m (FY 2024: € 50.9 m) } Adjusted Group EBITDA1 is expected to reach € 30 m to € 50 m (FY 2024: € 22.6 m) OUTLOOK 2028 } Group revenues CAGR2024-2028 targeted to be in a range of 8 – 12% } Adj. EBITDA margin 2028 expected to be above 20%

Guidance

Evotec 2025 Outlook: Expects Revenue Of €840M–€880M; And EBITDA of €30M–€50M, R&D Spend Of €40M-€50M

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.24) by 60.42 percent. This is a 46.15 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $208.23 million which missed the analyst consensus estimate of $215.46 million by 3.36 percent. This is a 8.14 percent decrease over sales of $226.69 million the same period last year.

Earnings Beats

Earnings Misses

Evotec Q1 EPS $(0.10) Beats $(0.24) Estimate, Sales $208.23M Miss $215.46M Estimate

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Evotec to report an earnings per share (EPS) of $-0.24.
Evotec bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.11 in the last quarter, leading to a 0.0% drop in the share price on the following day.
Here's a look at Evotec's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.100</td>
<td>-0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.065</td>
<td></td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>10.0%</td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746471727_0.png" alt="eps graph" />
<h3>Tracking Evotec's Stock Performance</h3>
Shares of Evotec were trading at $4.29 as of May 02. Over the last 52-week period, shares are down 17.9%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EVO/earnings">To track all earnings releases for Evotec visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Evotec

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec

Evotec Deepens CELMoDs Alliance With Bristol Myers Squibb As Molecular Glue Degrader Pipeline Expands

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday.
Shares of uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) rose sharply during Thursday's session after the company was granted FDA granted Breakthrough Therapy designation for AMT-130 for the treatment of <a href="https://www.benzinga.com/quote/QURE">Huntington&#8217;s disease.</a>
uniQure shares jumped 45.3% to $13.65 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) gained 21.4% to $22.49.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) rose 20.3% to $6.99 after Pershing Square Capital Management disclosed a stake via a 13F. CNBC reported that Pershing Square&#8217;s stake is 19.8%, through shares &amp; swaps.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 15.3% to $847.08 after the company announced topline Phase 3 results from its ACHIEVE-1 trial, which showed orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) rose 13.8% to $10.97.</li>
<li>ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) gained 13% to $13.02.</li>
<li>VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) rose 12% to $10.91.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) jumped 10.7% to $3.6200 following FY24 financial results.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 10.1% to $80.00. The move came as investors responded to news that billionaire investor Bill Ackman&#8217;s Pershing Square Capital Management significantly increased its stake in Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>).</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) gained 9.1% to $29.15 following second-quarter results.</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) shares jumped 7% to $73.41. Fidelity National Information Services unveiled two strategic moves—acquiring Global Payments' Issuer Solutions unit and selling its remaining stake in Worldpay.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) gained 4.4% to $76.40.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862443/intuit-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday">Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

CAPR

CLPT

DLTR

GPCR

IIIN

QURE

VBNK

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

WIIM

Evotec shares are trading higher. The company reported FY24 financial results.

<h3>Companies Reporting Before The Bell</h3>
• Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $250.69 million. 
• Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $23.92 billion. 
• Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $220.76 million. 
• Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is estimated to report quarterly earnings at $1.01 per share on revenue of $5.54 billion. 
• Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) is estimated to report quarterly earnings at $0.42 per share on revenue of $1.97 billion. 
• ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $3.96 billion. 
• State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) is likely to report quarterly earnings at $2.01 per share on revenue of $3.32 billion. 
• American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is expected to report quarterly earnings at $3.47 per share on revenue of $16.93 billion. 
• Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) is estimated to report quarterly earnings at $3.00 per share on revenue of $7.08 billion. 
• D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.03 billion. 
• Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) is projected to report quarterly earnings at $4.82 per share on revenue of $1.21 billion. 
• Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $363.15 million. 
• Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $2.16 billion. 
• Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) is estimated to report quarterly earnings at $0.95 per share on revenue of $283.30 million. 
• Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.83 billion. 
• Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) is likely to report quarterly earnings at $1.06 per share on revenue of $2.68 billion. 
• Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $4.94 billion. 
• UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is likely to report quarterly earnings at $7.29 per share on revenue of $111.60 billion. 
• Insteel Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $149.85 million. 
• Hooker Furnishings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFT#NASDAQ">HOFT</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $101.16 million. 
• Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $1.89 billion. 
• Infosys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $4.90 billion. 
• KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $1.75 billion. 
<h3>Companies Reporting After The Bell</h3>
• Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is expected to report quarterly earnings at $5.72 per share on revenue of $10.51 billion. 
• Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) is expected to report quarterly earnings at $1.16 per share on revenue of $175.04 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

FITB

HBAN

HOFT

INDB

INFY

NFLX

SCHW

TCBI

Earnings Scheduled For April 17, 2025

Guidance for full-year 2025
Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m)
R&amp;D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m)
Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)
Outlook 2028
Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 %
Adj. EBITDA margin 2028 expected to be above 20 %

Evotec 2025 Outlook: Revenues To Grow 5%-10%, Reaching €840M-€880M (Vs. €879.457M Est.), Sees Adj. EBITDA Of €30M-€50M; For 2028 Outlook, Expects 8%-12% CAGR And An EBITDA Margin Above 20%

Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) reported quarterly losses of €(1.11) per share which missed the analyst consensus estimate of €(0.75) by 48 percent. This is a 136.17 percent decrease over losses of €(0.47) per share from the same period last year. The company reported quarterly sales of € 797.00 million which missed the analyst consensus estimate of € 801.87 million by 0.61 percent.

Evotec FY 2024 GAAP EPS €(1.11) Misses €(0.75) Estimate, Sales €797.00M Miss €801.87M Estimate

<ul>
<li>Ongoing strategic partnership advances joint pipeline in neurodegeneration research</li>
<li>Evotec receives a $20 million payment to further progress research</li>
</ul>

Evotec Advances Neuroscience Partnership With Bristol Myers Squibb, Secures $20M For Neurodegeneration Research

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025
Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025

Management

Evotec Names Paul Hitchin As New CFO, Succeeding Laetitia Rouxel, Effective March 1, 2025

Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea
Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

Government

Evotec Partners with Yonsei University and Zymedi to Develop Lung Disease Therapies with $4.5M Grant

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Friday.
Shares of Ingles Markets, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMKTA#NASDAQ">IMKTA</a>) fell in today's pre-market trading after the company reported results for the three and twelve <a href="https://www.benzinga.com/quote/IMKTA/earnings">months ended Sept. 28</a>.
Net sales fell to $1.40 billion for the recent quarter, down from $1.58 billion in the year-ago period.
Ingles Markets shares fell 1.2% to $65.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Viemed Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) shares dipped 6.7% to $7.62 in pre-market trading after gaining 2% on Thursday.</li>
<li>Evotec SE  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 6.6% to $4.56 in pre-market trading following a 2% decline on Thursday.</li>
<li>Nabors Energy Transition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NETD#NASDAQ">NETD</a>) fell 6.3% to $10.11 in pre-market trading.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 4.8% to $10.31 in pre-market trading.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) shares declined 4.7% to $21.26 in pre-market trading.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) fell 3% to $24.37 in pre-market trading.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) dipped 2.6% to $13.30 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares slipped 0.7% to $451.12 in pre-market trading after declining around 1.8% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42698100/constellium-viracta-therapeutics-and-3-stocks-to-watch-heading-into-friday">Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

ACIC

APEI

IMKTA

MNSO

NETD

THRD

TSLA

Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<ul>
<li>Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases</li>
<li>LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions</li>
</ul>

Evotec And Novo Nordisk Launch First Projects For LAB eN² Accelerator, Focusing On Cardiometabolic Diseases

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Distribution of responsibilities internally
HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019.

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global Operations Leadership Team Until A New Organizational Structure Is Designed And Announced In Line With The Strategic Review

Press Releases

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Evotec Announces Change in Management Board

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Comments

Evotec

Evotec (EVO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル